Hypercoagulable States

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1. Which of the following will not result in an acquired hypercoagulable state?

1. Obesity
2. Pregnancy
3. Recent surgery
4. Nephrotic syndrome
5. None of the above

2. Which of the following has the most thrombogenic potential?

1. Prothrombin gene mutation
2. Factor V leiden
3. Hyperhomocysteinemia
4. Antithrombin III deficiency
5. Protein C deficiency

3. Which of the following is the most commonly seen in Caucasians?

1. Prothrombin gene mutation
2. Factor V leiden
3. Protein C deficiency
4. Protein S deficiency
5. Antithrombin III deficiency

4. Laboratory testing for which of the following is not affected by warfarin?

1. Protein C deficiency
2. Protein S deficiency
3. Prothrombin gene mutation
4. Antithrombin III deficiency
5. All of the above

5. Management of patients with Protein C deficiency includes?

1. Initiate pt’s presenting with VTE on heparin drip
2. Ensure aPTT or factor Xa levels therapeutic before initiating warfarin
3. Start low dose warfarin to avoid warfarin induced skin necrosis
4. Lifelong anticoagulation following spontaneous thromboembolic event
5. All of the above

6. Arterial thrombosis is reported but not typically associated with which of the following conditions?

1. Protein C deficiency
2. Factor V leiden
3. Prothrombin gene mutation
4. Antithrombin III deficiency
5. All of the above

7. Factor V leiden causes

1. Resistance of factor V to inactivation by activated protein C
2. Guanine to adenine substitution at nucleotide 20210 of the prothrombin gene
3. Unexplained recurrent late pregnancy loss
4. A and C
5. All of the above

8. Antiphospholipid antibody syndrome

1. Can cause false elevation in INR
2. Is difficult to diagnose because laboratory errors are very common
3. Is associated with venous or arterial thromboembolism and pregnancy morbidity
4. A and C
5. All of the above

9. Hyperhomocysteinemia is noted in patients with deficiencies in

1. Vitamin K
2. Folic Acid
3. Vitamin B6
4. Vitamin B12
5. B, C and D

10. Laboratory testing for hypercoagulable states should be?

1. Performed on each patient that presents with VTE
2. Reserved for patients presenting with suspected inherited thrombophilia based on family history or atypical presentation
3. Performed on patient who presents with VTE after 8 hour plane ride
4. Performed on patient who presents with VTE 1 week after surgery
5. A & B

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour